Strengthening of the Executive Leadership Team
BATAVIA, NY / ACCESSWIRE / September 21, 2022 / First Wave Technologies, Inc. (“First Wave”, “FWT” and the “Company”), a medical technology company developing products for acute and long-term care, announces that it has appointed Adi Raviv as Chief Financial Officer. Mr. Raviv will work closely with First Wave’s management and board of directors as the Company moves closer to initiating its clinical trials and 510(k) application for CLARITY-IA®, a next-generation inhalation anesthesia system.
Mr. Raviv comes to First Wave with significant experience as chief financial officer in the healthcare sector, as well as in capital markets, corporate finance, investment banking, investor relations and corporate transactions.
“As First Wave begins a new chapter in the development of CLARITY-IA, the Company’s primary goal will be to focus on clinical research in the areas of sedation and inhalation anesthesia. It will also be to further refine our CLARITY-IA platform technology to bring to market a simple, safe and economically viable solution for sedating patients and delivering inhaled anesthetics and therapeutics during mechanical ventilation. and in particular his healthcare and previous investment banking experience will be of tremendous value, especially at this important time,” said Brian Bell, founder and chief executive officer of First Wave.
“I am excited to be part of First Wave’s mission to make long-awaited and much-needed advances in the delivery of a range of inhaled medicines to patients. I look forward to First Wave working to advance CLARITY-IA and preparing clinical trials I will use my experience to support First Wave’s business development, product development, future growth and shareholder value,” added Mr. Raviv added.
In additional background, Mr. Raviv has served as CFO for several private and public companies and has served on the boards of many private and several public companies. He currently serves on the Board of Directors of BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), where he chairs the Audit and Finance Committees and is a member of the Compensation and Strategy Committees. He founded HTI Associates LLC in 1996 and has since served as a managing director of this management consulting firm, which also provides C-level outsourced functions. From 2021 to 2022, Mr. Raviv was interim CEO of Mirror Biologics, Inc., a clinical-stage biopharmaceutical company.
About First Wave Technologies, Inc.
First Wave Technologies, Inc. is a medical technology company that develops products for the acute and long-term care markets. The focus is on revolutionizing areas of healthcare with innovative products that have not historically undergone significant changes to improve patient care. Current products focus on improving the ease and accuracy of pharmaceutical administration. Visit http://firstwavetechnologies.com for more information.
Chief Executive Officer and Director
First Wave Technologies, Inc.
99 medical technology Dr.
Batavia, New York 14020
Telephone: +1 877.784.0269
Email: [email protected]
Jennifer K. Zimmons, Ph.D., MBA
Zimmon’s International Communications
Telephone: +1 917.214.3514
Email: [email protected]
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to our IsoVENT and our partnership with Canon. Such statements are subject to risks and uncertainties that could cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of the Company’s future performance. There can be no assurance that the events anticipated in the forward-looking statements will occur or, if they occur, what benefits the Company will derive. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions, which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those stated implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with the development and commercialization of technology and medical practice, (3 ) a change in health regulations, (4) any number of events or causes that may delay or stop the commercialization and development of the IsoVENT device, (5) the risk that the company will not implement its business plan or that the associated contractors developing and receiving regulatory approval for the IsoVENT device, failure to execute on their plans, (6) inability to retain key employees, (7) inability to fund operations and growth, and (8) others Factors beyond the Company’s control. These forward-looking statements are made as of the date of this press release and, except as required by law, the Company undertakes no obligation to update these forward-looking statements or to update the reasons why actual results differ from those projected in the forward-looking statements.
SOURCE: First Wave Technologies
View source version on accesswire.com: